The cross-border legal environment
China is the world's second-largest pharma market and an inseparable link in the global innovation chain. Whether a multinational introduces an innovative product into China, a Chinese company takes its own product global, or the two transact through technology licensing — cross-border deals face overlapping regimes: China's drug regulation, technology import/export controls, foreign exchange, cross-border data rules and international anti-bribery law (FCPA/UKBA).
License-in — importing global innovation
License-in is the main route for Chinese companies to access global innovative products. The typical structure: a Chinese company as licensee obtains exclusive rights to develop, register, manufacture and commercialise a drug in Greater China from an overseas pharma/biotech licensor.
Legal due diligence in license-in deals
- China registration feasibility: registration class, data-gap analysis (does foreign data support a China NDA, or is a Phase III bridging study required?) and timelines.
- Patent status and risk: China legal status of the target patents, third-party patents and FTO risk, and the impact of patent linkage.
- HGR assessment: whether the deal involves international cooperation or cross-border transfer of China HGR — and the approval/filing route.
- Technology import/export controls: whether the technology falls within the prohibited/restricted export catalogues.
- MAH eligibility: whether the licensee can act as China MAH.
License-out — Chinese innovation going global
Chinese innovators licensing products out to multinationals has grown explosively. Key China-law issues:
- Technology export licensing/filing: whether licensing patents and know-how abroad requires export permission or filing.
- HGR data provision: sharing China clinical data triggers HGR information-export filing or security review.
- Foreign exchange and tax: handling of upfront, milestone and royalty income.
- Sensitive-technology review: deals involving gene editing or AI drug discovery may require national-security assessment.
Multi-regional clinical trials (MRCT) in China
Multinationals include China in global Phase III MRCTs both to use Chinese patients and investigators and to satisfy China's "Chinese population data" requirement. China-compliance spans several dimensions:
- China IND and ethics: an MRCT still requires a China IND (or filing) and ethics approval at each site.
- HGR international-cooperation approval/filing: almost any MRCT touches Chinese data accessed by foreign sponsors/CROs — the question is approval vs. filing.
- Cross-border data transfer: the central database usually sits abroad; uploading China site data is a data export subject to PIPL and the Data Security Law.
- Sufficiency of Chinese-subject data: CDE requires the China subgroup's efficacy and safety data to be adequate and to contribute to overall conclusions.
Cross-border data flows — the special pharma challenge
- Trial data export: China patient data to overseas central databases.
- Pharmacovigilance data export: China adverse-event reports to global PV databases.
- Genetic data export (HGR): a doubly-regulated area — HGR rules plus the Data Security Law.
- Compliance routes: standard contractual clauses (SCC) filing, certification, or security assessment for "important data" export.
Import drug registration
- Pharmaceutical requirements: complete CMC data and acceptance of overseas on-site GMP inspection.
- Domestic agent liability: a foreign MAH must appoint a Chinese legal entity as agent, jointly and severally liable with the MAH.
- Chinese labelling: labels and instructions must be in Chinese and approved by CDE.